Patents by Inventor Myriam N. Bouchlaka

Myriam N. Bouchlaka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LILRB2 ANTIBODY PRODUCTS AND METHODS
    Publication number: 20240132589
    Abstract: The disclosure relates to LILRB2 antibody products and methods of use thereof. The antibody products specifically bind to LILRB2 on cells such as myeloid cells or cancer cells. The antibody products can be used in methods of treatment of disease, such as methods cancer immunotherapy.
    Type: Application
    Filed: October 17, 2023
    Publication date: April 25, 2024
    Inventors: Meghan Zuck, Peter Probst, Thomas J. Graddis, Myriam N. Bouchlaka Bay, Kamal D. Puri
  • Use of mesenchymal stem cell-educated macrophages to treat and prevent graft versus host disease and radiation-induced injury
    Patent number: 10166254
    Abstract: The present invention relates to methods for treating and preventing graft-versus-host disease (GVHD) and radiation-induced tissue damage or organ failure. More particularly, methods of the present invention comprise administering a therapeutically effective amount of mesenchymal stem cell-educated macrophages (MEMs) to a subject to treat or prevent GVHD, bone marrow failure, radiation-induced tissue damage or organ failure, or a condition associated with aberrant inflammation.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: January 1, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Peiman Hematti, Myriam N. Bouchlaka, Christian M. Capitini
  • USE OF MESENCHYMAL STEM CELL-EDUCATED MACROPHAGES TO TREAT AND PREVENT GRAFT VERSUS HOST DISEASE AND RADIATION-INDUCED INJURY
    Publication number: 20160082042
    Abstract: The present invention relates to methods for treating and preventing graft-versus-host disease (GVHD) and radiation-induced tissue damage or organ failure. More particularly, methods of the present invention comprise administering a therapeutically effective amount of mesenchymal stem cell-educated macrophages (MEMs) to a subject to treat or prevent GVHD, bone marrow failure, radiation-induced tissue damage or organ failure, or a condition associated with aberrant inflammation.
    Type: Application
    Filed: September 18, 2015
    Publication date: March 24, 2016
    Inventors: Peiman Hematti, Myriam N. Bouchlaka, Christian M. Capitini